[go: up one dir, main page]

MX2022010957A - Compuestos que se dirigen a las proteínas de unión al arn o a las proteínas modificadoras del arn. - Google Patents

Compuestos que se dirigen a las proteínas de unión al arn o a las proteínas modificadoras del arn.

Info

Publication number
MX2022010957A
MX2022010957A MX2022010957A MX2022010957A MX2022010957A MX 2022010957 A MX2022010957 A MX 2022010957A MX 2022010957 A MX2022010957 A MX 2022010957A MX 2022010957 A MX2022010957 A MX 2022010957A MX 2022010957 A MX2022010957 A MX 2022010957A
Authority
MX
Mexico
Prior art keywords
rna
proteins
compounds targeting
modifying
binding proteins
Prior art date
Application number
MX2022010957A
Other languages
English (en)
Inventor
Shomir Ghosh
Darren Martin Harvey
Anna M Ericsson
Original Assignee
Twentyeight Seven Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Twentyeight Seven Inc filed Critical Twentyeight Seven Inc
Publication of MX2022010957A publication Critical patent/MX2022010957A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se relaciona con un compuesto representado por la Fórmula (I): (ver formula), o una sal farmacéuticamente aceptable de este, composiciones que lo comprenden y métodos para prepararlo y utilizarlo. Las variables se describen en este documento.
MX2022010957A 2020-03-03 2021-03-02 Compuestos que se dirigen a las proteínas de unión al arn o a las proteínas modificadoras del arn. MX2022010957A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062984677P 2020-03-03 2020-03-03
PCT/US2021/020494 WO2021178420A1 (en) 2020-03-03 2021-03-02 Compounds targeting rna-binding proteins or rna-modifying proteins

Publications (1)

Publication Number Publication Date
MX2022010957A true MX2022010957A (es) 2023-01-24

Family

ID=75223420

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010957A MX2022010957A (es) 2020-03-03 2021-03-02 Compuestos que se dirigen a las proteínas de unión al arn o a las proteínas modificadoras del arn.

Country Status (12)

Country Link
US (1) US20240254136A1 (es)
EP (1) EP4114831A1 (es)
JP (1) JP2023517539A (es)
KR (1) KR20230022829A (es)
CN (1) CN116157392A (es)
AU (1) AU2021231765A1 (es)
BR (1) BR112022017574A2 (es)
CA (1) CA3170415A1 (es)
IL (1) IL296137A (es)
MX (1) MX2022010957A (es)
TW (1) TW202146398A (es)
WO (1) WO2021178420A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
JP2023137325A (ja) * 2022-03-18 2023-09-29 日清食品ホールディングス株式会社 ２－アセチル－１－ピロリンの製造方法
AU2024282281A1 (en) * 2023-06-02 2026-01-15 Westol, Llc 2,8-dihydroxyquinoline glucuronide derivatives with enhanced properties for use as anticancer, antiviral, antimicrobial, and other therapeutic applications
CN118666744B (zh) * 2024-08-26 2024-11-08 成都天兴致远生物科技有限公司 一种奈诺沙星关键中间体的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US756011A (en) 1903-06-01 1904-03-29 James L Fitz Gerald Gasolene-motor.
JP3370324B2 (ja) 1991-04-25 2003-01-27 中外製薬株式会社 ヒトインターロイキン−６受容体に対する再構成ヒト抗体
AU735186B2 (en) * 1997-09-15 2001-07-05 Warner Chilcott Company, Llc Antimicrobial quinolones, their compositions and uses
JPH11147883A (ja) * 1997-11-14 1999-06-02 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸誘導体、そのエステルまたはこれらの塩
GB2442951B (en) * 2006-08-10 2011-02-23 Univ Jordan Anticancer and antibacterial agents
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2011031740A1 (en) * 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
CN102101859A (zh) * 2009-12-16 2011-06-22 中山大学 一类喹喏酮羧酸衍生物及其用途
EP2688595B1 (en) * 2011-03-25 2018-03-14 Children's Medical Center Corporation Lin28-mediated control of let-7 biogenesis
UY36714A (es) * 2015-06-09 2016-12-30 Bayer Pharma Akttiengesellschaft Moduladores alostéricos positivos del receptor muscarínico m2
WO2017156557A1 (en) 2016-03-07 2017-09-14 Northeast Ohio Medical University Animal model for studying zcchc6 in bone disease and development
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
US20190201489A1 (en) 2016-06-28 2019-07-04 Northeast Ohio Medical University Compositions and methods for preventing bone loss and/or stimulating bone healing
AU2018238079B2 (en) * 2017-03-24 2022-03-03 Wakunaga Pharmaceutical Co., Ltd. Novel pyridone carboxylic acid derivative or salt thereof

Also Published As

Publication number Publication date
AU2021231765A1 (en) 2022-10-06
TW202146398A (zh) 2021-12-16
WO2021178420A1 (en) 2021-09-10
US20240254136A1 (en) 2024-08-01
CA3170415A1 (en) 2021-09-10
CN116157392A (zh) 2023-05-23
JP2023517539A (ja) 2023-04-26
BR112022017574A2 (pt) 2022-11-16
IL296137A (en) 2022-11-01
KR20230022829A (ko) 2023-02-16
EP4114831A1 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
MX2022010957A (es) Compuestos que se dirigen a las proteínas de unión al arn o a las proteínas modificadoras del arn.
PH12021552482A1 (en) Compounds targeting prmt5
MX2025000642A (es) Compuestos macrociclicos para el tratamiento de cancer
MX2024000299A (es) Compuestos antivirales.
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
ZA202206923B (en) New methylquinazolinone derivatives
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
MX2021003739A (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
WO2019178191A8 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
AU2020231934A8 (en) Compounds useful in HIV therapy
PH12021552533A1 (en) Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
PH12021552513A1 (en) Pyrrole compounds
PH12022550433A1 (en) Heterocyclic compounds
WO2021094505A8 (en) Herbicidal compounds
PH12021550439A1 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
PH12021552953A1 (en) Tricyclic compounds
MX2021006692A (es) Proceso mejorado para preparar ozanimod.
JOP20210353A1 (ar) مركبات وطرق استخدامها كعوامل مضادة للجراثيم
PH12022551012A1 (en) 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease
MX2024006176A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno.
JOP20220084A1 (ar) مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
WO2020251871A3 (en) Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors